13F Holdings
中文EN

IXHL Incannex Healthcare Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1873875 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY69.0%
TTM EPS YoY97.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-20.7%
ROA-19.9%
ROIC (approx.)-1,944.8%
Asset turnover—

Leverage & solvency

Liabilities / assets6.0%
Debt / equity0.00x
Current ratio67.79x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.21x
Accruals ratio-15.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-06-30FY20252025-06-30FY20242024-06-30FY20232023-06-30FY2022*2022-06-30
Income statement
Revenue$0$86,000$12,000——
Cost of revenue————$6,338
R&D expense$5.21M$10.75M$12.88M$6.31M$5.37M
SG&A expense$17.82M$13.13M$17.17M$8.01M—
Operating income-$23.03M-$23.79M-$30.04M-$49.67M—
Interest expense$0$303,000———
Pretax income-$19.30M-$46.88M-$18.43M-$48.81M-$14.90M
Income tax$0$0$30,000——
Net income-$19.30M-$46.88M-$18.46M-$48.81M-$14.90M
EBITDA-$22.79M-$23.54M-$29.94M-$49.58M—
EPS (basic)-1.66-40.82-1.15-3.32-1.25
EPS (diluted)-1.66-40.82-1.15-3.32-1.25
Weighted avg. shares (diluted)11.66M1.15M16.16M15.38M—
Banking
Deposits————$86.59M
Balance sheet
Cash & equivalents$67.71M$15.04M$5.86M$22.12M$25.83M
Receivables———$287,478$294,717
Current assets$72.83M$19.96M$16.20M$23.00M$37.88M
PP&E, net$4,000$227,000$472,000$294,000—
Intangibles———$52.72M—
Total assets$72.98M$20.45M$17.05M$23.78M$37.88M
Current liabilities$1.49M$6.98M$5.62M$2.55M$2.01M
Total liabilities$5.61M$7.06M$5.83M$2.96M$2.01M
Shareholders' equity$67.37M$13.39M$11.22M$20.82M$24.71M
Shares outstanding12.54M6.48M17.64M15.87M—
Cash flow statement
Operating cash flow-$12.87M-$12.51M-$15.85M-$10.75M-$12.81M
Capital expenditure$10,000$8,000$277,000$316,000—
Free cash flow-$12.88M-$12.52M-$16.12M-$11.06M—
Investing cash flow-$94,000-$8,000-$277,000-$316,000—
Financing cash flow$65.90M$21.40M—$8.18M$41.18M
Depreciation & amortization$240,000$246,000$103,000$88,000—
Stock-based compensation$7.56M$2.61M$8.93M$2.15M$1.46M
Share buybacks$9.40M$0———

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.